InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
43%
T+90 mean return
-1.0%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Caeymaex Emmanuel, Executive. Officer active across 1 company, notably UCB. Cumulatively, 14 disclosures have been logged. History available since 27 August 2025. The latest transaction was filed on 8 April 2026 (Sale). Regulator: FSMA. The full history is free.
Declarations14 total
7,937 shares@ €266.700.0047% mcap29.4% of flowShareEuronext BrusselsFSMA:ucb-33
7,937 shares@ €102.040.0018% mcap11.2% of flowShareOff exchangeFSMA:ucb-86
Ideal exit: 3 Jan 2027 (T+270)
1,010 shares@ €271.800.0006% mcap3.8% of flowShareEuronext BrusselsFSMA:ucb-62
4,031 shares0Options /warrants for employees or managersOff exchangeFSMA:ucb-129
Ideal exit: 2 Jan 2027 (T+270)
3,528 shares0ShareOff exchangeFSMA:ucb-60
Ideal exit: 27 Dec 2026 (T+270)
3,000 shares@ €254.2710.6% of flowShareEuronext BrusselsFSMA:ucb-198
3,000 shares@ €79.993.3% of flowShareOff exchangeFSMA:ucb-187
Ideal exit: 5 Oct 2026 (T+270)
966 shares@ €76.211.0% of flowShareOff exchangeFSMA:ucb-179
Ideal exit: 15 Sept 2026 (T+270)
966 shares@ €238.503.2% of flowShareEuronext BrusselsFSMA:ucb-226
3,000 shares@ €79.993.3% of flowShareOff exchangeFSMA:ucb-191
Ideal exit: 15 Sept 2026 (T+270)
3,000 shares@ €238.309.9% of flowShareEuronext BrusselsFSMA:ucb-112
1,500 shares@ €248.905.2% of flowShareEuronext BrusselsFSMA:ucb-52
1,500 shares@ €247.655.2% of flowShareEuronext BrusselsFSMA:ucb-183
5,000 shares@ €200.6813.9% of flowShareEuronext BrusselsFSMA:ucb-128
14 of 14 declarations
About Caeymaex Emmanuel
Emmanuel Caeymaex is a senior executive at UCB, a global biopharmaceutical company. In his role, he is responsible for the strategic direction and management of the company's operations. Caeymaex plays a key role in developing innovative solutions for patients, focusing on research and development. His experience in the pharmaceutical industry enables him to contribute effectively to UCB's evolution in the global market.
